We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why
Read MoreHide Full Article
TherapeuticsMD, Inc. (TXMD - Free Report) announced that the FDA has accepted the resubmission of the New Drug Application (“NDA”) for its dyspareunia candidate, TX-004HR. The FDA also set a PDUFA date of May 29, 2018.
Shares of the company however fell 6.8% in after-hours trading on Dec 19, presumably due to classification of resubmission as a Class 2 response by the FDA. Classification as a Class 1 response would have shortened the timeframe for a potential approval from six months to two months.
We remind investors that the company had received a complete response letter (“CRL”) from the FDA in May for the same.
However, TherapeuticsMD’s share price has increased 6.4% in the past six months, outperforming the industry’s decline 0.4%.
TX-400HR is an applicator-free vaginal estradiol softgel drug for the treatment of moderate-to- severe vaginal pain during sexual intercourse (dyspareunia) due to vulvar and vaginal atrophy (VVA) in post-menopausal women.
The resubmission was supported by data from phase III Rejoice study, which demonstrated statistically significant and clinically meaningful improvements in dyspareunia and vaginal dryness from baseline compared to a placebo.
We note that the resubmission includes data only for two dosages – 4 mcg and 10 mcg – of the candidate.
The CRL was a major setback for the company. Any issue with the resubmission may further delay the candidate’s approval and result in a decline in shares.
According to the press release, an estimated 32 million women are currently suffering from symptoms of VVA in the United States.
We note that in April 2017, AMAG Pharmaceuticals, Inc. had acquired commercial rights to Intrarosa, the only FDA-approved non-estrogen product for the treatment of moderate-to-severe dyspareunia from privately held Endoceutics, Inc.
Celldex’s loss estimates narrowed from $1.03 to 93 cents for 2017 and from 96 cents to 90 cents over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.36%.
ACADIA’s loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why
TherapeuticsMD, Inc. (TXMD - Free Report) announced that the FDA has accepted the resubmission of the New Drug Application (“NDA”) for its dyspareunia candidate, TX-004HR. The FDA also set a PDUFA date of May 29, 2018.
Shares of the company however fell 6.8% in after-hours trading on Dec 19, presumably due to classification of resubmission as a Class 2 response by the FDA. Classification as a Class 1 response would have shortened the timeframe for a potential approval from six months to two months.
We remind investors that the company had received a complete response letter (“CRL”) from the FDA in May for the same.
However, TherapeuticsMD’s share price has increased 6.4% in the past six months, outperforming the industry’s decline 0.4%.
TX-400HR is an applicator-free vaginal estradiol softgel drug for the treatment of moderate-to- severe vaginal pain during sexual intercourse (dyspareunia) due to vulvar and vaginal atrophy (VVA) in post-menopausal women.
The resubmission was supported by data from phase III Rejoice study, which demonstrated statistically significant and clinically meaningful improvements in dyspareunia and vaginal dryness from baseline compared to a placebo.
We note that the resubmission includes data only for two dosages – 4 mcg and 10 mcg – of the candidate.
The CRL was a major setback for the company. Any issue with the resubmission may further delay the candidate’s approval and result in a decline in shares.
According to the press release, an estimated 32 million women are currently suffering from symptoms of VVA in the United States.
We note that in April 2017, AMAG Pharmaceuticals, Inc. had acquired commercial rights to Intrarosa, the only FDA-approved non-estrogen product for the treatment of moderate-to-severe dyspareunia from privately held Endoceutics, Inc.
TherapeuticsMD, Inc. Price
TherapeuticsMD, Inc. Price | TherapeuticsMD, Inc. Quote
Zacks Rank & Stocks to Consider
TherapeuticsMD carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. (CLDX - Free Report) and ACADIA Pharmaceuticals Inc. (ACAD - Free Report) . Both the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Celldex’s loss estimates narrowed from $1.03 to 93 cents for 2017 and from 96 cents to 90 cents over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.36%.
ACADIA’s loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>